Compugen Ltd

CGEN XNAS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

210M

Short interest (May 15)

1.8%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.67%

↑ 14.8%

Available Shares

400K

↓ 56.0%

Price Chart

Company Overview

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Company Info

Exchange: NASDAQ

CIK: 0001119774

Asset Type: CS

Market Data

Market Cap: $213,761,277

Employees: 75

Status: Active

Short Interest

Current Borrow Fee 0.67%

Range: 0.67% - 0.74%

Available Shares 400K

Range: 400K - 450K

Recent Changes

Fee Change: ↑ 8.8%

Available Change: ↓ 22.7%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime